Inflammatory response after influenza vaccination in men with and without carotid artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 12, 2006, Pages 2738-2744

  Carty, Cara L ^a   Heagerty, Patrick ^b   Nakayama, Karen ^b   McClung, E Clair ^b   Lewis, Julieann ^b   Lum, Dawn ^b   Boespflug, Erin ^b   McCloud Gehring, Carrie ^c   Soleimani, Behrooz R ^b   Ranchalis, Jane ^b   Bacus, Tamara J ^b   Furlong, Clement E ^b   Jarvik, Gail P ^b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Department of Biostatistics ^*  (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Acute phase response; Carotid artery disease; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID A PROTEIN; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; INFLUENZA VACCINE; INTERLEUKIN 6; STATIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DISEASE MARKER; DISEASE SEVERITY; DRUG USE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE;

ACUTE-PHASE REACTION; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CONSTRICTION, PATHOLOGIC; DISEASE SUSCEPTIBILITY; HUMANS; INFLAMMATION; INFLUENZA VACCINES; INTERLEUKIN-6; LINEAR MODELS; MALE; MIDDLE AGED; QUESTIONNAIRES; SERUM AMYLOID A PROTEIN;

EID: 33751176257     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000248534.30057.b5     Document Type: Article

References (43)

1. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-3488.
2. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258:1183-1186.
3. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242.
4. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Tracy RP, Rubin SM, Harris TB, Pahor M. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol. 2003;92:522-528.
5. Lowe GDO. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Throm Haemost. 2005;3:1618-1627.
6. Marquardt L, Ruf A, Mansmann U, Winter R, Buggle F, Kallenberg K, Grau AJ. Inflammatory response after acute ischemic stroke. J Neurol Sci. 2005;236:65-71.
7. Kutuk O, Basaga H. Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med. 2003;9:549-557.
8. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195-2224.
9. Verschuur M, van der Beek MT, Tak HS, Visser LG, de Maat MP. Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination. Blood Coagul Fibrinolysis. 2004;15:399-404.
10. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first time acute myocardial infarction. Lancet. 1998;351:1467-1471.
11. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of Myocardial Infarction and Stroke after Acute Infection of Vaccination. N Engl J Med. 2004;351:2611-2618.
12. Syrjanen J, Teppo AM, Valtonen VV, Iivanainen M, Maury CP. Acute phase response in cerebral infarction. J Clin Pathol. 1989;42:63-68.
13. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, Margolin S, Rieder M, Nickerson D, Schellenberg GD, Heagerty PJ, Furlong CE. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol. 2003a;23:1465-1471.
14. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388.
15. Bachorik PS, Albers JJ. Precipitation methods for quantification of lipoproteins. Methods Enzymol. 1986;129:78-100.
16. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 1986;129:101-123.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
19. Kolb H, Worz-Pagenstert U, Kleemann R, Rothe H, Rowsell P, Rastegar S, Scott FW. Insulin therapy of prediabetes suppresses TH1 associated gene expression in BB rat pancreas. Autoimmunity. 1997;26:1-6.
20. Thompson D, Harrison SP, Evans SW, Whicher JT. Insulin modulation of acute-phase protein production in a human hepatoma cell line. Cytokine. 1991;3:619-626.
21. Tsai MY, Hanson NQ, Straka RJ, Hoke TR, Ordovas JM, Peacock JM, Arends VL, Arnett DK. Effect of influenza vaccine on markers of inflammation and lipid profile. J Lab Clin Med. 2005;145:323-327.
22. van der Beek M, Visser L, de Maat M. Yellow fever vaccination as a model to study the response to stimulation of the inflammation system. Vascul Pharmacol. 2002;39:117-121.
23. Wilkins J, Gallimore JR, Tennent GA, Hawkins PN, Limburg PC, van Rijswijk MH, Moore EG, Pepys MB. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem. 1994;40:1284-1290.
24. Ozawa A, Konishi F, Nagai H, Okada M, Kanazawa K. Cytokine and Hormonal Responses in Laparoscopic-Assisted Colectomy and Conventional Open Colectomy. Surgery Today. 2000;30:107-111.
25. Falsey AR, Walsh EE, Francis CW, Looney RJ, Kolassa JE, Hall WJ, Abraham GN. Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. The Journal of Infectious Diseases. 2001;183:995-999.
26. Di Napoli M, Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke. 2002;33:1763-1771.
27. Beamer NB, Coull BM, Clark WM, Briley DP, Wynn M, Sexton G. Persistent inflammatory response in stroke survivors. Neurology. 1998;50:1722-1728.
28. Di Napoli MP, F. Bocola V. C-Reactive Protein in Ischemic Stroke: An Independent Prognostic Factor. Stroke. 2001;32:917-924.
29. Woodward M, Lowe GDO, Campbell DJ, Colman S, Rumley A, Chalmers J, Neal BC, Patel A, Jenkins AJ, Kemp BE, MacMahon SW. Associations of Inflammatory and Hemostatic Variables with the Risk of Recurrent Stroke. Stroke. 2005;36:2143-2147.
30. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956-959.
31. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-235.
32. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am J Med. 2001;110:62S-65S.
33. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793-798.
34. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J, Chait A. Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes. Arterioscler Thromb Vasc Biol. 2006;18:18.
35. Segrest JP, Li L, Anantharamaiah GM, Harvey SC, Liadaki KN, Zannis V. Structure and function of apolipoprotein A-I and high-density lipoprotein. Current Opinion in Lipidology. 2000;11:205-215.
36. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001;103:2283-2288.
37. Eriksen N, Benditt EP. Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein. Proc Natl Acad Sci U S A. 1980;77:6860-6864.
38. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994;15:81-88.
39. Bedossa P, Poynard T, Abella A, Paraf F, Lemaigre G, Martin E. Localization of apolipoprotein A-I and apolipoprotein A-II in human atherosclerotic arteries. Arch Pathol Lab Med. 1989;113:777-780.
40. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN, Chait A. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation. 1998;98:519-527.
41. O'Brien KD, McDonald TO, Kunjathoor V, Eng K, Knopp EA, Lewis K, Lopez R, Kirk EA, Chait A, Wight TN, deBeer FC, LeBoeuf RC. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:785-790.
42. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93:198-200.
43. Kaplan M. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol. 2006;18:289-297.